Post by
sunshine7 on Mar 18, 2016 11:28am
I reiterate...
CXR would not have added 100 sales folks to the previous 75 assigned to US Donnatal product if they were concerned about earnings. This is not the behaviour of a company that is concerned about debt payment risk or meeting guidance. IMO they will meet guidance next Wed and CXR SP will surpass VRX.
Comment by
DeathPool on Mar 18, 2016 11:39am
Sunshine7, Most pharma sales reps have commission based compensation packages. Its like Future Shop increasing their sales force - no sales, no comp and nothing lost. Sorry, I just don't see adding sales reps as a valid argument that supports an optimistic report. Just my opinion.
Comment by
JustforFun7 on Mar 18, 2016 12:11pm
even if they dont meet guidance...as long as they show an ability to pay downdebt and the new business numers dont look too bad, there is a lot of upside to this. What he says will have as much as impact as the numbers. Lots of info needed. JFF7
Comment by
Windsorman on Mar 18, 2016 1:37pm
I agree totally with your premise. Expect CEO to emphasize that the debt is managable and is being reduced each quarter. I expect the revenue numbers to be inline with guidance and positive outlook. I have been buying the last couple days as Valeant effect has desimated CRX shares. Great long term investment IMHO. GLTA